ORIGINAL RESEARCH article
Front. Psychiatry
Sec. Mood Disorders
Volume 16 - 2025 | doi: 10.3389/fpsyt.2025.1610520
A network-based approach to discover diagnostic metabolite markers associated with depressive features for major depressive disorder
Provisionally accepted- 1Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China
- 2Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Despite the high prevalence of major depressive disorder (MDD), current diagnostic methods rely on subjective clinical assessments, highlighting the need for biomarkers. This study aimed to investigate plasma metabolite signatures in patients with MDD compared with healthy controls (HC) and to identify diagnostic biomarkers associated with depressive features.Methods A total of 99 patients with MDD and 50 HC were included in this study from a study cohort. Targeted plasma metabolomics was employed to quantify metabolites across diverse biochemical classes. Weighted gene co-expression network analysis (WGCNA) was performed to construct metabolite networks and identify modules and metabolites associated with depressive features. Diagnostic models were developed based on the identified hub metabolites, using six supervised machine-learning algorithms. Model interpretability was enhanced through the application of the SHapley Additive exPlanations (SHAP) algorithm.ResultsPathways such as biosynthesis of phenylalanine, tyrosine and tryptophan, glutathione metabolism, and arginine and proline metabolism were significantly enriched in the comparison of metabolic profiles between the MDD and HC groups. Seven hub metabolites were identified as the biomarker signatures that effectively discriminate the MDD and HC groups. Among these metabolites, one sphingomyelin (SM (OH) C16:1), one hexosylceramide (HexCer(d18:1/24:1)), one phosphatidylcholine (PC aa C40:6), and one cholesteryl ester (CE(20:4)) were positively associated with the depression severity, sadness/depressive mood, and other depressive features, while methionine, arginine, and tyrosine showed negative correlation. The deep neural network model incorporating these seven biomarkers achieved the highest diagnostic performance, with an area under the curve (AUC) of 0.803 (95% CI, 0.643–0.962).Conclusion We identified a novel signature of seven biomarkers for constructing an explainable diagnostic model that effectively discriminates between the MDD and HC groups. These biomarkers were associated with depressive symptoms. The findings provide new insights into the biological diagnosis of MDD.
Keywords: Major Depressive Disorder, Metabolomics, biomarkers, machine-learning, WGCNA
Received: 12 Apr 2025; Accepted: 12 May 2025.
Copyright: © 2025 Zheng, Zeng, Tian, Li, He and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Huafang Li, Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200013, Shanghai Municipality, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.